MTOR and cancer: Similarly, in another cancer type SCLS, we observed strong correlations (r ≥ 0.6)between predicted and observed metric values for similar drugs targeting the PI3K/MTOR pathway (Supplementary Fig. 12b), but not for those drugs targeting the ERK/MAPK signalling pathway.